Shilpa Medicare receives approval for Pemetrexed Injection in Europe

24 Jan 2022 , 10:15 AM

Shilpa Medicare’s Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml, Ready to use formulation has been approved by European Authorities, through its agreed partners in Europe. The product will be manufactured, for EU commercialization at its own EU GMP compliant, injectable manufacturing facility situated in Telangana state.

Shilpa has developed Pemetrexed formulation as liquid/ ready to use injection, against lyophilized powder formulation of reference, ALIMTA.

Shilpa’s Pemetrexed Injection is a unique formulation, which is supplied as ready to use formulation without any further dilution. The product is stable at room temperature. Pemetrexed injection is used in the treatment of malignant pleural mesothelioma & non-small cell lung cancer.

According to IQVIA MAT Q2’2021 (June 2021) data, the EU market for Pemetrexed Injection is approximately EURO 519 Million.

On Sensex, Shilpa Medicare was trading at Rs534.05 per share down by Rs2.6 or 0.48%, at around 10:15 AM.